The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib study of tepotinib in EGFR-mutant/c-Met-positive NSCLC: Final data and long-term responders.
 
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Pfizer; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Roche
Research Funding - Boehringer Ingelheim (Inst); Roche (Inst)
 
Ross A. Soo
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Merck; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche
Research Funding - AstraZeneca; Bayer; Merck Serono; Novartis; Pfizer; Roche; SERVIER; Taiho Pharmaceutical
 
Dong-Wan Kim
No Relationships to Disclose
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; MSD; Novartis; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Yuhan
 
Jürgen Scheele
Employment - Merck KGaA
Research Funding - Merck KGaA
 
Wenfeng Chen
Employment - Merck Serono
 
Andreas Becker
Employment - Merck KGaA
 
Keunchil Park
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Clovis Oncology; Hanmi; Kyowa Hakko Kirin; Lilly; Novartis; Ono Pharmaceutical; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - AstraZeneca